Baltimore, United States
Previse is a biotechnology startup founded in 2020 with a mission to revolutionize cancer detection, starting with esophageal cancer. Through innovative technology developed by the GI Early Detection Biomarker Lab at Johns Hopkins University School of Medicine, Previse aims to provide earlier detection and prevention of cancer, ultimately saving lives.
Esophageal cancer is a deadly disease, claiming 16,000 lives annually in the United States due to late detection and limited treatment options. Previse addresses this challenge by offering a non-invasive, cost-effective, and accurate early-detection system that utilizes patented DNA biomarkers to test for the disease. This system can be integrated into routine care, empowering individuals to receive necessary treatment before symptoms arise, thus improving their chances of survival.
The startup recently secured a $1.80M grant investment from the National Institute of Diabetes and Digestive and Kidney Diseases on 11 October 2023, demonstrating recognition and support from respected institutions.
Previse's innovative approach and potential to impact cancer care make it a compelling investment opportunity in the biotechnology industry, with promising prospects for positive societal and economic outcomes.
